Business Context and Reporting Period
Company: MUSTANG BIO, INC. (MBIO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended March 31, 2026
Business Overview: Mustang Bio is a clinical-stage biopharmaceutical company focused on developing CAR T-cell therapies and oncolytic viruses for solid tumors, specifically malignant brain tumors. The company is a majority-controlled subsidiary of Fortress Biotech, Inc. It has no approved products and has not generated product revenue.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(955,000) | $(153,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.14) | $(0.05) |
| Cash and Cash Equivalents (End of Period) | $16,258,000 | $14,231,000 |
| Total Assets | $16,582,000 | $17,593,000 |
| Total Liabilities | $7,986,000 | $8,064,000 |
| Accumulated Deficit | $(399,599,000) | $(396,876,000) |
| Operating Cash Flow | $(1,008,000) | $(1,389,000) |
Note: All figures in thousands except per share data.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased to $0.96 million in Q1 2026 from $0.15 million in Q1 2025. This increase is primarily due to the absence of non-recurring gains recorded in Q1 2025, specifically a $0.4 million gain from lease termination and $0.7 million in savings from the settlement of aged payables.
- Operating Expenses: Total operating expenses rose to $1.06 million in Q1 2026 from $0.25 million in Q1 2025.
- R&D Expenses: Reported as $0.18 million in Q1 2026 compared to a net benefit of $(0.96) million in Q1 2025 (due to the aforementioned lease gain and payable settlements).
- G&A Expenses: Decreased to $0.88 million in Q1 2026 from $1.22 million in Q1 2025, driven by lower stock-based compensation and reduced financing-related service costs.
- Liquidity: Cash balances decreased by approximately $1.0 million during the quarter due to operating losses, with no financing or investing cash flows in Q1 2026.
Outlook, Risks, and Management Commentary
- Liquidity Position: Management believes current cash of $16.3 million is sufficient to fund operations for at least 12 months from the filing date. The company expects to continue incurring significant operating losses.
- Capital Raising Constraints: The company is subject to SEC "baby shelf rules" (General Instruction I.B.6 to Form S-3) because its public float is less than $75 million. This limits the amount of securities it can sell in any 12-month period to one-third of its public float.
- Nasdaq Compliance Risk: On April 15, 2026, the company received notice from Nasdaq that its stock bid price had closed below $1.00 for 30 consecutive business days. It has a 180-day grace period (until October 12, 2026) to regain compliance. Failure to do so could result in delisting.
- Development Pipeline: The company is exploring the initiation of an investigator-sponsored single-institution trial for its combination therapy (MB-109) in Q3 2026. No products are approved for commercial sale.
- Related Party Transactions: The company relies on Fortress Biotech for management services and office space. Fortress controls a voting majority of the company and receives an annual stock dividend (2.5% of fully-diluted equity), causing dilution to other shareholders.
Investor Verification Checklist
- Nasdaq Delisting Risk: Verify the current stock bid price and the company's specific plan to regain compliance with the $1.00 minimum bid price requirement by October 2026.
- Cash Runway: Confirm the 12-month liquidity projection given the continued burn rate and the inability to raise significant capital under current "baby shelf" restrictions.
- Related Party Dilution: Review the impact of the annual 2.5% stock dividend paid to Fortress Biotech on existing shareholder equity.
- Lease Termination Impact: Understand that Q1 2025 results were artificially improved by one-time gains; Q1 2026 reflects a more normalized expense structure.
- Deferred Payments: Note the $1.3 million deferred payment obligation to uBriGene, which can be delayed if net assets remain below $20 million, currently accruing interest.